Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report)’s stock price was up 16.5% during trading on Friday. The stock traded as high as $4.8922 and last traded at $4.80. Approximately 207,566 shares changed hands during trading, a decline of 93% from the average session volume of 2,798,922 shares. The stock had previously closed at $4.12.
Entero Therapeutics Trading Up 3.5%
The stock’s 50-day moving average is $3.47 and its 200-day moving average is $3.62. The stock has a market cap of $7.89 million, a price-to-earnings ratio of -2.94 and a beta of 1.19.
About Entero Therapeutics
Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing orally delivered therapies for gastrointestinal diseases and disorders. The company’s research and development efforts are aimed at addressing conditions with limited treatment options, including diseases involving impaired digestion and intestinal inflammation.
Entero’s lead product candidate is adrulipase, an orally administered recombinant enzyme being developed as a potential treatment for exocrine pancreatic insufficiency, a condition in which the pancreas does not produce enough digestive enzymes.
Further Reading
- Five stocks we like better than Entero Therapeutics
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
- Why Wall Street Expects Even More From SanDisk After Its 575% Rally
- The Grocery Shelf Battle Is Changing—Who Comes Out Ahead?
- 3 Unique ETFs With Strong Momentum for the End of the Year
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
